377 related articles for article (PubMed ID: 33721621)
1. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
Cascone T; Sacks RL; Subbiah IM; Drobnitzky N; Piha-Paul SA; Hong DS; Hess KR; Amini B; Bhatt T; Fu S; Naing A; Janku F; Karp D; Falchook GS; Conley AP; Sherman SI; Meric-Bernstam F; Ryan AJ; Heymach JV; Subbiah V
ESMO Open; 2021 Apr; 6(2):100079. PubMed ID: 33721621
[TBL] [Abstract][Full Text] [Related]
2. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
[TBL] [Abstract][Full Text] [Related]
4. Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.
Pedersen KS; Grierson PM; Picus J; Lockhart AC; Roth BJ; Liu J; Morton A; Chan E; Huffman J; Liang C; Wang-Gillam A; Tan B
Invest New Drugs; 2021 Oct; 39(5):1298-1305. PubMed ID: 33738668
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
Zhu M; Molina JR; Dy GK; Croghan GA; Qi Y; Glockner J; Hanson LJ; Roos MM; Tan AD; Adjei AA
Invest New Drugs; 2020 Dec; 38(6):1755-1762. PubMed ID: 32328844
[TBL] [Abstract][Full Text] [Related]
6. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
7. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
Rodrigues HV; Ke D; Lim J; Stephen B; Bellido J; Janku F; Zinner R; Tsimberidou A; Hong D; Piha-Paul S; Fu S; Naing A; Subbiah V; Karp D; Falchook G; Kurzrock R; Wheler J
Invest New Drugs; 2015 Jun; 33(3):700-9. PubMed ID: 25902899
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
9. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
[TBL] [Abstract][Full Text] [Related]
10. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
[TBL] [Abstract][Full Text] [Related]
11. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
[TBL] [Abstract][Full Text] [Related]
13. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study.
Phadnis S; Wang X; Daw NC; Herzog CE; Subbiah IM; Zaky W; Gouda MA; Morani AC; Amini B; Harrison DJ; Piha-Paul SA; Meric-Bernstam F; Gorlick R; Schwartz CL; Subbiah V
ESMO Open; 2023 Dec; 8(6):101609. PubMed ID: 37879233
[TBL] [Abstract][Full Text] [Related]
14. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
[TBL] [Abstract][Full Text] [Related]
15. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
Curigliano G; Martin M; Jhaveri K; Beck JT; Tortora G; Fazio N; Maur M; Hubner RA; Lahner H; Donnet V; Ajipa O; Li Z; Blumenstein L; Andre F
Eur J Cancer; 2021 Jul; 151():49-62. PubMed ID: 33964572
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Deeken JF; Wang H; Subramaniam D; He AR; Hwang J; Marshall JL; Urso CE; Wang Y; Ramos C; Steadman K; Pishvaian MJ
Cancer; 2015 May; 121(10):1645-53. PubMed ID: 25641763
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
Bullock KE; Petros WP; Younis I; Uronis HE; Morse MA; Blobe GC; Zafar SY; Gockerman JP; Lager JJ; Truax R; Meadows KL; Howard LA; O'Neill MM; Broadwater G; Hurwitz HI; Bendell JC
Cancer Chemother Pharmacol; 2011 Feb; 67(2):465-74. PubMed ID: 21079958
[TBL] [Abstract][Full Text] [Related]
18. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
Park H; Williams K; Trikalinos NA; Larson S; Tan B; Waqar S; Suresh R; Morgensztern D; Van Tine BA; Govindan R; Luo J; Lockhart AC; Wang-Gillam A
Cancer Chemother Pharmacol; 2021 Mar; 87(3):337-347. PubMed ID: 33159216
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.
Vlahovic G; Meadows KL; Uronis HE; Morse MA; Blobe GC; Riedel RF; Zafar SY; Alvarez-Secord A; Gockerman J; Starodub AN; Ready NE; Anderson EL; Bendell JC; Hurwitz HI
Cancer Chemother Pharmacol; 2012 Jul; 70(1):95-102. PubMed ID: 22638798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]